throbber
11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`Page 1
`
`AMNEAL PHARMACEUTICALS LLC
`and
`AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,
`Petitioners,
`V.
`INC.
`ALLERGAN,
`Patent Owner
`
`Case: IPR2018-00608
`U.S. Patent No. 9,161,926
`
`NORRIS MCLAUGHLIN, P.A.
`400 CROSSING BOULEVARD - 8TH FLOOR
`BRIDGEWATER, NEW JERSEY
`08807
`NOVEMBER 20, 2018
`10:03 A.M.
`
`ORAL DEPOSITION OF
`BOZENA B. MICHNIAK-KOHN, PH.D., FAAPS, M.R.PHARM.S.
`
`REPORTED BY:
`DEBRA SAPIO LYONS, RDR, CRR, CRC, CCR, CLR, CPE
`
`DIGITAL EVIDENCE GROUP
`1730 M Street, NW, Suite 812
`Washington, D.C. 20036
`(202) 232-0646
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`1 of 241
`
`Almirall EXHIBIT 2053
`Amneal v. Almirall
`IPR2018-00608
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 2
`
`1
`
`2
`
`November 20, 2018
`
`Oral deposition of Bozena B.
`
`3 Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.,
`
`4
`
`5
`
`6
`
`7
`
`held at the offices of Norris McLaughlin,
`
`P.A., 400 Crossing Boulevard - 8th Floor,
`
`Bridgewater, New Jersey 08807, before Debra
`
`Sapio Lyons, a Registered Diplomat Reporter, a
`
`s Certified Realtime Reporter, a Certified
`
`Realtime Captioner, a Certified LiveNote
`
`Reporter, an Approved Reporter of the United
`
`States District Court for the Eastern District
`
`of Pennsylvania, a Certified Court Reporter of
`
`the State of New Jersey, a Notary Public of
`
`the States of New Jersey, New York and the
`
`Commonwealth of Pennsylvania.
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`2 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 3
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`APPEARANCES:
`
`STERNE KESSLER GOLDSTEIN FOX
`
`BY:
`
`ADAM C. LAROCK, ESQUIRE
`
`DENNIES VARUGHESE, PHARM.D,
`
`ESQUIRE
`
`1100 New York Ave. N.W., Suite 600
`
`Washington, D.C. 20005
`
`202.772.8794
`
`202.772.8805
`
`alarock@sternekessler.com
`
`dvarughe@sternekessler.com
`
`Attorneys for Petitioners
`
`FENWICK & WEST LLP
`
`BY:
`
`ELIZABETH B. HAGAN, PH.D., ESQUIRE
`
`1191 Second Avenue, 10th Floor
`
`Washington, D.C. 98101
`
`206.389.4587
`
`ehagan@fenwick.com
`
`Attorneys for Patent Owner
`
`ALSO PRESENT:
`
`LARS TAAVOLA, ESQUIRE
`
`Senior Patent Counsel, Global Intellectual
`
`Property
`
`Amneal Pharmaceuticals
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`3 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 4
`
`1
`
`2 WITNESS
`
`I N D E X
`
`PAGE
`
`9
`
`PAGE
`
`8
`
`Bozena B. Michniak-Kohn, Ph.D., FAAPS,
`
`M.R.Pharm.S.
`
`EXAMINATION
`
`BY MS. HAGAN
`
`E X H I B I T S
`
`NUMBER
`
`DESCRIPTION
`
`Exhibit Michniak-Kohn 1, Declaration
`
`of Bozena B. Michniak-Kohn Ph.D.
`
`FAAPS, M.R.Pharm.S. bearing Bates
`
`Numbers AMN1002
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Exhibit Michniak-Kohn 2, Curriculum
`
`8
`
`Vitae B. Michniak-Kohn January 2018
`
`bearing Bates Numbers AMN1003,
`
`Exhibit Michniak-Kohn 3, United
`
`30
`
`States Patent Number 9,161,926 B2,
`
`bearing Bates Numbers AMN1001
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`4 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`EXHIBITS (Continued)
`
`NUMBER
`
`DESCRIPTION
`
`Exhibit Michniak-Kohn 4,
`
`PAGE
`
`41
`
`Page 5
`
`International Publication Number
`
`WO 2009/061298 Al bearing Bates
`
`Numbers AMN1004
`
`Exhibit Michniak-Kohn 5, Pub. Number
`
`44
`
`U.S. 2006/0204526 Al, United States
`
`Patent Application Publication,
`
`Lathrop, et al., bearing Bates
`
`Numbers AMN1006
`
`Exhibit Michniak-Kohn 6, document
`
`56
`
`titled Diethylene glycol monoethyl
`
`ether:
`
`an emerging solvent in
`
`topical dermatology products by
`
`David W. Osborne, Ph.D., bearing
`
`Bates Numbers AMN1009
`
`Exhibit Michniak-Kohn 7,
`
`84
`
`International Publication Number
`
`WO 2010/072958 A2 bearing Bates
`
`Numbers AMN1005
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`5 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`EXHIBITS (Continued)
`
`NUMBER
`
`DESCRIPTION
`
`Exhibit Michniak-Kohn 8,
`
`PAGE
`
`189
`
`Page 6
`
`United States Patent Application
`
`Publication Guo, et al., Publication
`
`Number U.S. 2007/0190019 Al bearing
`
`Bates Numbers AMN1013
`
`Exhibit Michniak-Kohn 9, multipage
`
`194
`
`article entitled Characterization and
`
`Stability of Emulsion Gels Based on
`
`Acrylamide/Sodium Acryloyldimethyl
`
`Taurate Copolymer by Giuila
`
`Bonacucina, et al., bearing Bates
`
`Numbers AMN1015,
`
`Exhibit Michniak-Kohn 10, multipage
`
`208
`
`Pharmaceutical Bulletin entitled
`
`Lubrizol Pharmaceutical Bulletin 21
`
`bearing Bates Numbers AMN1021
`
`Exhibit Michniak-Kohn 11, document
`
`218
`
`titled Seppic SepineoTM P 600. The
`
`3-in-1 polymer for pharmacy bearing
`
`Bates Numbers AMN1026
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`6 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 7
`
`EXHIBITS (Continued)
`
`NUMBER
`
`DESCRIPTION
`
`Exhibit Michniak-Kohn 12,
`
`PAGE
`
`223
`
`United States Patent, Orsoni, et al.,
`
`Patent Number U.S. 7,820,186 B2
`
`bearing Bates Numbers AMN1011
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`7 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`(Exhibit Michniak-Kohn 1,
`
`Declaration of Bozena B. Michniak-Kohn
`
`Ph.D. FAAPS, M.R.Pharm.S. bearing Bates
`
`Numbers AMN1002, is marked for
`
`identification.)
`
`(Exhibit Michniak-Kohn 2,
`
`Curriculum Vitae B. Michniak-Kohn
`
`January 2018 bearing Bates Numbers
`
`AMN1003, is marked for identification.)
`
`BOZENA B. MICHNIAK-KOHN, PH.D.,
`
`FAAPS, M.R.PHARM.S., having been first
`
`duly sworn, was examined and testified
`
`as follows:
`
`MS. HAGAN: Good morning.
`
`I'm
`
`Elizabeth Hagan for Fenwick -- of
`
`Fenwick & West for parent owner
`
`Almirall, LLC.
`
`MR. LaROCK:
`
`I'm Adam LaRock from
`
`Sterne, Kessler law firm for
`
`Petitioners. With me is also Dennies
`
`Varughese from Sterne, Kessler and
`
`Lars Taavola from Amneal.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`8 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`EXAMINATION
`
`BY MS. HAGAN:
`
`Q.
`
`A.
`
`Q.
`
`Good morning.
`
`Good morning.
`
`Thank you for coming.
`
`I
`
`understand that you have some issues regarding
`
`sitting and standing, so we'll work out as
`
`best we can and try to keep you comfortable
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Thank you.
`
`-- throughout the process.
`
`I appreciate it.
`
`Absolutely.
`
`Can you, please, state your full
`
`name?
`
`A.
`
`Bozena, B middle initial,
`
`17 Michniak-Kohn.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Q.
`
`A.
`
`And where do you live?
`
`25 Riverview Avenue in
`
`Piscataway, New Jersey 08854.
`
`Q.
`
`A.
`
`How are you employed?
`
`I am employed by Rutgers
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`9 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`1 University full time.
`
`I'm a full professor
`
`Page 10
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`there with tenure in the Ernest Mario School
`
`of Pharmacy on Busch Campus.
`
`Q.
`
`And what is the address of the
`
`office where you work?
`
`A.
`
`145 Bevier -- that's
`
`B-E-V-I-E-R -- Road, Piscataway, New Jersey
`
`08854.
`
`Q.
`
`Have you ever testified in any
`
`type of a proceeding?
`
`A.
`
`Q.
`
`Yes,
`
`I have.
`
`Have you had your deposition
`
`taken before?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Many times
`
`All right.
`
`yes.
`
`So you're quite familiar with
`
`this process then, but just to get this out of
`
`the way, I'm going to be asking you questions
`
`and hopefully getting answers from you. Our
`
`questions -- my questions and your answers
`
`22 will be transcribed by the court reporter.
`
`I
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`10 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`1 will try not to speak when you are speaking;
`
`Page 11
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`and I ask that you also try not to speak when
`
`I am speaking. All right?
`
`A.
`
`Q.
`
`Understood.
`
`Great.
`
`Did you do anything to prepare
`
`for the deposition today?
`
`A.
`
`Yes,
`
`I did. And before I answer
`
`that totally, I have some corrections as well
`
`that -- that were picked up.
`
`Q.
`
`A.
`
`Okay.
`
`In my first report, Paragraph 61
`
`on Page 33 and Paragraph 90 on Page 56 there
`
`is a reference missing.
`
`Q.
`
`I'm sorry. When you say your
`
`"first report," are you referring to the
`
`declaration you submitted on behalf of Amneal
`
`in this IPR?
`
`A.
`
`Yes, because I submitted two
`
`declarations, so it's the first declaration.
`
`Q.
`
`You submitted -- what is your
`
`second declaration?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`11 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`1
`
`A.
`
`There's a second declaration as
`
`2 well.
`
`Page 12
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`MR. LaROCK: There was a -- there
`
`was a supplemental declaration to --
`
`THE WITNESS: A supplemental.
`
`That's the correct term.
`
`MR. LaROCK:
`
`-- moot some
`
`objections that your prior counsel made.
`
`MS. HAGAN: When was that
`
`submitted?
`
`MR. LaROCK: September.
`
`MS. HAGAN:
`
`Do you know the
`
`exhibit number?
`
`MR. LaROCK: No, they aren't
`
`filed. They're just served.
`
`MS. HAGAN: And to whom were they
`
`served?
`
`MR. LaROCK: Scott Kamholz of
`
`Covington --
`
`MS. HAGAN: Okay.
`
`MR. LaROCK:
`
`-- patent owner's
`
`counsel.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`12 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 13
`
`MS. HAGAN: Right. We don't have
`
`that. Would you, please, provide that
`
`to us?
`
`MR. LaROCK: Sure. We can see
`
`what we can do.
`
`MS. HAGAN:
`
`Thank you.
`
`BY MS. HAGAN:
`
`Q.
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`So your first report or -(cid:173)
`
`Declaration.
`
`-- declaration you said Page 33?
`
`Yes, Page 33, Paragraph 61.
`
`Hold on just a moment, please.
`
`So Page 33 I have the end of
`
`Paragraph 57 and Paragraph 58.
`
`A.
`
`So it's paragraph -- end of
`
`Paragraph 61.
`
`Q.
`
`Hold on just a minute and let me
`
`give you a copy of your declaration.
`
`A.
`
`Q.
`
`Please.
`
`So before we get started, I've
`
`handed you two documents marked as
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22 Michniak-Kohn Exhibit 1 --
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`13 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`MR. LaROCK: Do you have a copy?
`
`Page 14
`
`BY MS. HAGAN:
`
`Q.
`
`-- and Michniak-Kohn Exhibit 2.
`
`MS. HAGAN: Absolutely. And
`
`here's another one.
`
`MR. VARUGHESE: Oh, thanks.
`
`MS. HAGAN: And the stapler was
`
`not that fantastic on the second one -(cid:173)
`
`MR. LaROCK: Oh.
`
`MS. HAGAN:
`
`-- so there may be
`
`some loose pages for the CV.
`
`Could we, please, get a copy of
`
`the second declaration at break?
`
`MR. LaROCK: Yeah, we can see
`
`what we can do, but you should have
`
`gotten everything from prior counsel
`
`before coming to the deposition today.
`
`MS. HAGAN: Great. But if you
`
`can look for it, and I assume that you
`
`have a copy somewhere, can get it to us
`
`in some format, that's fine.
`
`MR. LaROCK:
`
`I don't actually
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`14 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`have a copy, nor a printer here since
`
`we're not at our offices, so we'll see
`
`what we can do.
`
`MS. HAGAN: Electronic would be
`
`great. Okay.
`
`MR. LaROCK: Okay.
`
`MS. HAGAN: Thanks.
`
`THE WITNESS:
`
`So it's
`
`Paragraph 61 on Page 36.
`
`BY MS. HAGAN:
`
`Q.
`
`A.
`
`Q.
`
`A.
`
`Okay.
`
`My apologies.
`
`I said 33.
`
`All right.
`
`It's 36. And if we look at
`
`Line 1, 2, 3, 4 -- Line 5 there is a reference
`
`AMNl 010
`
`Q.
`
`A.
`
`Uh-huh.
`
`that stays, but what is
`
`19 missing there in addition is the Guo, G-U-O,
`
`20
`
`21
`
`22
`
`reference, and the Guo reference number is
`
`1013. And the same occurred on Paragraph 90.
`
`Q.
`
`I'm sorry. Do you have a pin
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`15 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`cite for that or just Guo generally?
`
`A.
`
`I just -- sorry.
`
`I just said it.
`
`It is AMN1013 is Guo.
`
`Q.
`
`Was there any particular page
`
`that you were citing to in that Guo reference
`
`for this citation?
`
`A.
`
`No, it was -- it was the
`
`reference. That refers to -- any page that
`
`refers to Sepineo in Guo.
`
`I don't remember
`
`unless I look at Guo.
`
`Q.
`
`So you don't have a specific page
`
`cite?
`
`yeah.
`
`A.
`
`I don't have a specific page,
`
`Q.
`
`Thank you.
`
`Okay. And the second one?
`
`A.
`
`Paragraph 90, and I believe that
`
`is on Page 56 or starts on Page 56, and on
`
`Page 57 we see (AMN1010, 1), to that we need
`
`to, again, add the Guo reference.
`
`Q.
`
`And, again, no specific page
`
`cite
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`16 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`A.
`
`Q.
`
`No specific.
`
`within the Guo reference?
`
`All right. Are there any other
`
`clarifications you would like to make before
`
`we get started?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`That was all.
`
`Okay.
`
`Thank you.
`
`You have a Ph.D. in pharmacology;
`
`is that correct?
`
`A.
`
`Q.
`
`Yes,
`
`I do.
`
`And you earned your Ph.D. in 1980
`
`from DeMontfort University in Leicester,
`
`England; is that correct?
`
`A.
`
`Q.
`
`That is correct.
`
`You are also a licensed member of
`
`the Royal Pharmaceutical Society of Great
`
`18 Britain; correct?
`
`19
`
`20
`
`21
`
`22
`
`A.
`
`Q.
`
`A.
`
`That is correct.
`
`What does that mean?
`
`That means that I am a registered
`
`pharmacist and able to, even currently because
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`17 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`I've kept up my license, it's the equivalent
`
`of the United States licensure of the
`
`boards -- State Board of Pharmacy that allows
`
`a pharmacy-educated person to practice the art
`
`of pharmacy.
`
`Q.
`
`So you are allowed to be a
`
`dispensing pharmacist in Great Britain
`
`according to that licensure?
`
`A.
`
`Q.
`
`That is correct.
`
`Is there anything that you need
`
`to do for maintenance of that license?
`
`A.
`
`Yes.
`
`In fact, I have to provide
`
`always the continuing education; and the fact
`
`that I publish, in fact, counts for continuing
`
`education, that I'm in the science anyway
`
`already counts.
`
`Q.
`
`And as part of your current
`
`employment at Rutgers, you are the Director of
`
`the Laboratory for Drug Delivery at New Jersey
`
`Center for Biomaterials; is that correct?
`
`A.
`
`Q.
`
`That is correct.
`
`And you've been in that position
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`18 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 19
`
`1
`
`2
`
`3
`
`from around September of 2000 to the present?
`
`A.
`
`Q.
`
`That is correct.
`
`And you are also the Founder and
`
`4 Director of the Center For Dermal Research at
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`the NJCBM; is that correct?
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Yes, that is correct
`
`And --
`
`-- at Rutgers, uh-huh.
`
`Does the NJCBM stand for the New
`
`Jersey Center for Biomaterials?
`
`A.
`
`Q.
`
`It does.
`
`What would you say is the
`
`authoritative text on current trends in
`
`research on topical pharmaceutical
`
`compositions?
`
`BY MS. HAGAN:
`
`MR. LaROCK: Objection to form.
`
`Q.
`
`A.
`
`You may answer if you have one.
`
`I think basically there are many
`
`texts from Marcel Dekker series that talks
`
`about percutaneous absorption and formulation.
`
`And there's a whole series of books that cover
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`19 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`that topic. There are what are called kind of
`
`pharmaceutical encyclopedias that cover more,
`
`obviously, than just topical, that cover all
`
`aspects of formulation such as Remington's,
`
`5 Ansel, and Stoklosa that we use to teach
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`students from, and many, many others.
`
`And, of course, there's a lot of
`
`publications because formulation is a science
`
`and an art, so people try things that may be
`
`not in the books and then publish.
`
`So that
`
`all gathered, there -- there's a lot of
`
`information out and available.
`
`Q.
`
`So if I was a formulator and
`
`trying to keep up with the current trends in
`
`research, are there any particular journals
`
`that you would point me to?
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS: Well, formulation
`
`can come up in many types of journals
`
`from many disciplines --
`
`BY MS. HAGAN:
`
`Q.
`
`Let's --
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`20 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 21
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`A.
`
`Q.
`
`so --
`
`stick to topical
`
`pharmaceutical compositions.
`
`A.
`
`Q.
`
`A.
`
`Indeed, that would still apply.
`
`Great.
`
`Because I'm thinking there are
`
`what are known as material science journals as
`
`s well as pharmaceutical journals that --
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`polymer journals that cover different -- you
`
`know, wide aspects and aren't necessarily just
`
`pharmaceutical journals by definition that can
`
`cover formulation aspects. You know, somebody
`
`may have discovered a new polymer that has
`
`topical applications, and that may appear in
`
`what would be known in colloquial terms in a
`
`polymer journal.
`
`So there are many, in other
`
`words.
`
`Q.
`
`I've handed you a document marked
`
`as Exhibit 1 titled, "Declaration of Bozena B.
`
`20 Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S" and
`
`21
`
`22
`
`bearing the label AMN1002 in the lower right
`
`corner of the first page.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`21 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Do you recognize this document?
`
`A.
`
`Q.
`
`Yes,
`
`I do.
`
`Is it the first declaration you
`
`submitted on behalf of Amneal in this matter?
`
`A.
`
`Q.
`
`Yes, it is.
`
`And is it the document to which
`
`you were giving corrections earlier?
`
`A.
`
`Q.
`
`That is correct.
`
`I've also handed you a document
`
`that's been marked as Exhibit 2 with the words
`
`"Curriculum Vitae" and "Name: Bozena
`
`'Bo' B.
`
`Michniak-Kohn" at the top and the label
`
`AMN1003 in the lower right corner of the first
`
`page.
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`Do you recognize this document?
`
`Yes,
`
`I do.
`
`What is it?
`
`It's my CV as of January 2018.
`
`I assume that you may have a - -
`
`more recent publications than are listed in
`
`that CV; is that correct?
`
`A.
`
`That is probably correct, yes.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`22 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`Q.
`
`With that exception, are there
`
`any other changes or updates to the CV from
`
`January 2018 to now?
`
`A.
`
`Well, there's probably more
`
`abstracts, posters, presentations during the
`
`year, perhaps some organizational awards or
`
`updates, funding updates probably because
`
`s we're nearly at the end of -- of the year, so
`
`9
`
`those sections probably need updating. You
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`know, postdoctoral experiences, appointments
`
`are probably the same.
`
`Q.
`
`So the
`
`your current
`
`appointments are the same as here?
`
`A.
`
`Q.
`
`Yes, they are.
`
`Okay. On Page 3 of your CV you
`
`list "Research Interests and Experience."
`
`Do you see that?
`
`Yes.
`
`And you include, "Optimization of
`
`A.
`
`Q.
`
`topical, transdermal and transmucosal drug
`
`delivery"; is that correct?
`
`A.
`
`That is correct.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`23 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 24
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`Q.
`
`What do you mean here by
`
`"optimization"?
`
`A.
`
`I use that word to kind of cover
`
`the broad scope of the type of work that we
`
`do. That may span from starting with a new
`
`drug that may not have been applied
`
`topically -- for example, or act
`
`another
`
`active -- when I say "active," a
`
`non-pharmaceutical, for example vitamins or
`
`other sometimes personal care or even cosmetic
`
`agents in some cases -- through to coming up
`
`12 with the formulation, the testing of
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`formulations to answer questions like:
`
`"Is
`
`the active going into the skin and where it's
`
`going into the skin?"
`
`We also, you know, optimize a
`
`particular formulation in the sense that we
`
`start with one version and then look at other
`
`ingredients, other excipients, the influence
`
`of what we're doing.
`
`I mean, I'm talking very
`
`generally. Obviously it's project specific.
`
`But I tried to use language that was broad
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`24 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 25
`
`1
`
`2
`
`3
`
`enough to cover the types of things we do.
`
`Q.
`
`Understood. And if we turn to
`
`your declaration, Exhibit -- what's been
`
`4 marked as Exhibit 1, and looking at
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Paragraph 6 of your declaration, which begins
`
`on page -- is on Page 4, your declaration
`
`states that you are "an expert in the field of
`
`topical pharmaceutical compositions and
`
`transdermal drug delivery systems"; is that
`
`correct?
`
`A.
`
`Q.
`
`That is correct.
`
`And what do you mean here by "the
`
`field of topical pharmaceutical compositions"?
`
`A.
`
`Pharmaceutical compositions of
`
`various excipients and also actives that are
`
`applied to the skin with the intention of
`
`either delivering to the skin or across the
`
`skin for transdermal drug delivery systems.
`
`And I've spent 40 years now looking and
`
`researching in that area.
`
`Q.
`
`And when you say here
`
`"pharmaceutical," what does that mean,
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`25 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`particularly in this instance?
`
`Page 26
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS: We look at, as I
`
`already kind of alluded to in -- a few
`
`minutes ago, that we look at drugs,
`
`either pharmaceutical, over-the-counter
`
`or new -- new compounds, that are
`
`intended ultimately for patient use.
`
`And I also look at what I would
`
`classify as personal care actives. And
`
`occasionally, this is not the main focus
`
`of what we do, some cosmetic actives.
`
`In other words, non-pharmaceutical or at
`
`concentrations that are
`
`non-pharmaceuticals.
`
`BY MS. HAGAN:
`
`Q.
`
`You, when you just gave that
`
`answer, you listed both pharmaceutical and
`
`over-the-counter.
`
`Do those have different meanings
`
`or is over-the-counter a subset of
`
`pharmaceutical?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`26 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 27
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`A.
`
`That would be a sub --
`
`pharmaceutical would cover both, so
`
`prescription and non-prescription,
`
`over-the-counter pharmaceutical. Things that
`
`are approved by the FDA for patient use.
`
`Q.
`
`Thank you.
`
`The same paragraph says that you
`
`have, and you just alluded to, a lot of
`
`experience, 37 to 40 years of experience of
`
`designing and testing novel formulations for
`
`topical and transdermal drug delivery systems;
`
`correct?
`
`A.
`
`Q.
`
`Correct.
`
`Have you ever designed any
`
`topical pharmaceutical formulations that were
`
`improvements upon an existing FDA-approved
`
`topical pharmaceutical formulation?
`
`A.
`
`Q.
`
`Yes,
`
`I have.
`
`When you have done that, is there
`
`any particular place where you start when you
`
`formulate or design a formulation that's an
`
`improvement upon an FDA-approved formulation?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`27 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 28
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`A.
`
`It de --
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS:
`
`It depends very
`
`much on the project and what the -- what
`
`the objective is and what the drug is.
`
`BY MS. HAGAN
`
`Q.
`
`If your goal was improved
`
`efficacy with the same active agent or active
`
`ingredient, would that affect where you start?
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS: Again, it would
`
`depend on what drug this is, what the
`
`previous dosage form is, and what the
`
`objective of the changed formulation is.
`
`BY MS. HAGAN:
`
`Q.
`
`Would you consider the previous
`
`FDA-approved formulation when developing an
`
`improved formulation?
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS: Again, it would
`
`depend on what the study entails and
`
`what you mean by consideration.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`28 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`s
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`I mean, would I know about it?
`
`I -- I would, but how -- how useful is
`
`that information would be, again, it
`
`would depend on the case.
`
`BY MS. HAGAN:
`
`Q.
`
`In Paragraph 13 you include a
`
`table of documents. And the statement at the
`
`top of that table says, "In formulating my
`
`opinion, I have considered all documents cited
`
`herein, including the following."
`
`Is this table a complete list of
`
`documents that you considered in formulating
`
`the opinion expressed in this declaration?
`
`A.
`
`Q.
`
`Yes, of the exhibits, yes, it is.
`
`Is there anything outside of
`
`those exhibits that you considered in
`
`formulating the opinion expressed in this
`
`declaration?
`
`A.
`
`Apart from my own knowledge and
`
`skill, no.
`
`Q.
`
`And if you go back to Page 3
`
`I'm sorry, Paragraph 3 which is on Page 3, you
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`29 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 30
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`state that, "In preparing this declaration, I
`
`have reviewed the '926 Patent" -- and that's
`
`AMN1001 -- "and considered each of the
`
`documents cited therein."
`
`MS. HAGAN: And, actually, to
`
`make things easier, I'm going to ask
`
`that an exhibit be marked here.
`
`(Exhibit Michniak-Kohn 3, United
`
`States Patent Number 9,161,926 B2,
`
`bearing Bates Numbers AMN1001, is marked
`
`for identification.)
`
`BY MS. HAGAN:
`
`Q.
`
`So you've been handed an exhibit
`
`14 marked Exhibit 3, and at the top it says,
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`"United States Patent Warner et al. Patent
`
`Number U.S. 9,161,926 B2. And at the bottom
`
`right corner its says AMN1001.
`
`Do you recognize this document?
`
`Yes,
`
`I do.
`
`Is this the '926 Patent that you
`
`A.
`
`Q.
`
`are referring to in your declaration?
`
`A.
`
`Yes, this is that patent.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`30 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Q.
`
`Okay. Thank you.
`
`So going back to Paragraph 3 of
`
`Page 31
`
`your declaration, it says you reviewed the
`
`'926 Patent and considered each of the
`
`documents cited therein; correct?
`
`A.
`
`Q.
`
`That is correct.
`
`What documents cited in the
`
`'926 Patent did you consider?
`
`A.
`
`(Reviewing document.)
`
`So we have the -- on the patent,
`
`56 the References Cited, for example, the
`
`Osborne, Patent Number 5,863,560 is the
`
`equivalent on my Page 7 of the declaration
`
`document or Exhibit Number 1016, which we're
`
`calling the Osborne II reference.
`
`We then see in Column 2, Lathrop
`
`et al., 2006/0204526 Al, and that is my
`
`Exhibit Number 1007, and it's called in
`
`in
`
`quotes "Lathrop" reference on my Page 7 of the
`
`declaration.
`
`Q.
`
`Did you consider the other --
`
`MR. LaROCK:
`
`She wasn't done,
`
`I
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`31 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Page 32
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`don't think.
`
`THE WITNESS: No, because I'm -(cid:173)
`
`I'm looking at Morris, and I know I had
`
`a Morris reference, but I don't recall
`
`the patent number.
`
`Morris, here you are.
`
`'781, yes.
`
`So Column 2 of the '926 Patent refers to
`
`2010/0029781 Al by Morris. And Morris
`
`is in my exhibits Number 1008 called and
`
`referred to as the Morris reference.
`
`There may be others, but those
`
`are the ones I recognize right now.
`
`BY MS. HAGAN:
`
`Q.
`
`Okay. Do you recall whether you
`
`considered the other two Osborne patents
`
`listed on Page 1 of Exhibit 3? That would be
`
`Patent 6,060,085 or Patent 6,620,435.
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS: They are not listed
`
`in my exhibits that I considered, I
`
`don't think.
`
`BY MS. HAGAN:
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`32 of 241
`
`

`

`11/20/2018
`
`Amneal, et al. v. Allergan, Inc.
`
`Bozena B. Michniak-Kohn
`
`Q.
`
`I agree they're not listed there.
`
`But do you recall whether you
`
`Page 33
`
`considered them?
`
`MR. LaROCK: Objection to form.
`
`THE WITNESS:
`
`I don't think so.
`
`BY MS. HAGAN:
`
`Q.
`
`Thank you.
`
`Okay. Turning to Paragraph 17 of
`
`your declaration, you state, "In my opinion a
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`POSA" -- P-O-S-A -- "would work as part of a
`
`11 multi-disciplinary team."
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`And you -- POSA here, I believe,
`
`refers to person of ordinary skill in the art;
`
`is that correct?
`
`A.
`
`Q.
`
`correctly?
`
`A.
`
`Q.
`
`That is correct.
`
`Did I read that statement
`
`You did.
`
`Why in your opinion would a POSA
`
`work as part of a multi-disciplinary team?
`
`A.
`
`Because in Paragraph 18 if we
`
`look at the definition of a hypothetical POSA
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence G

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket